Awaiting evidence-based recommendations on prophylaxis in adult patients

Haemophilia

Volumn 16, Issue 6, 2010, Pages 955-956

  Tagliaferri, A ^a  

^a UNIVERSITY HOSPITAL OF PARMA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT BLOOD CLOTTING FACTOR 8;

BLEEDING; CLINICAL TRIAL; COST BENEFIT ANALYSIS; DRUG EFFICACY; DRUG SAFETY; EVIDENCE BASED MEDICINE; FOLLOW UP; HEMOPHILIA A; HEMOSTASIS; HUMAN; JOINT STABILITY; LETTER; PATIENT COMPLIANCE; PRIORITY JOURNAL; QUALITY OF LIFE; THROMBOSIS; TREATMENT OUTCOME;

ADOLESCENT; ADULT; CHILD; COAGULANTS; COST-BENEFIT ANALYSIS; EVIDENCE-BASED MEDICINE; HEMOPHILIA A; HEMORRHAGE; HUMANS; MIDDLE AGED; QUALITY OF LIFE; YOUNG ADULT;

EID: 78049278337     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2010.02340.x     Document Type: Letter

References (7)

1. Valentino LA. Controversies regarding the prophylactic management of adults with severe haemophilia A. Haemophilia 2009; 15(Suppl. 2): 5-22.
2. Trial to Evaluate the Effect of Secondary Prophylaxis with rFVIII Therapy in Severe Hemophilia A Adult Subjects Compared to That of Episodic Treatment (SPINART). Clinical Trials.gov web site. Available at Accessed January 20, 2010.
3. Tagliaferri A, Rivolta G, Coppola A et al. Prophylaxis versus on-demand therapy through economic report (P.O.T.T.E.R.) study. JTH 2009; 7(Suppl. 2): 567 [abstract].
4. Miners AH, Sabin CA, Tolley KH, Lee CA. Assessing the effectiveness and cost-effectiveness of prophylaxis against bleeding in patients with severe haemophilia and severe von Willebrand's disease. J Intern Med 1998; 244: 515-22.
5. Tagliaferri A, Coppola A, Franchini M et al. Effects of secondary prophylaxis started in adolescent and adult haemophiliacs. Haemophilia 2008; 14: 945-51.
6. Fischer K, Van Dijk K, Van den Berg HM. Late prophylaxis for severe hemophilia: effects of prophylaxis started in adulthood. J Thromb Haemost 2005; 1: OR205 [abstract].
7. Collins P, Faradji A, Morfini M, Enriquez MM, Scharntz L. Efficacy and safety of secondary ptophylactic vs. on-demand sucrose-formulated recombinant factor VIII treatment in adults with severe hemophilia A: results from a 13 month crossover study. J Thromb Haemost 2010; 8: 83-9.